Navigation Links
Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Date:9/5/2007

bout Melanoma

Malignant melanoma is the most deadly form of skin cancer. The incidence of this disease is increasing by approximately 4% annually in the U.S. In 2004, the American Cancer Society estimates more than 55,000 cases of malignant melanoma will have been diagnosed. Melanoma is the number one cause of cancer death in women aged 25 to 29. More information about melanoma can be accessed at the Melanoma Research Foundation: http://www.melanoma.org.

About the EADO

The EADO is an international cooperative group dedicated to promote, coordinate and improve clinical and laboratory research activities in skin cancer. Further information about the EADO can be viewed at: http://www.eado.org/.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements wit
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
2. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
3. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
4. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
5. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
8. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Glades Drugs, an independent ... is proud to announce its expansion into a new corporate ... will feature an 8,000-square-foot office space and state of the ... applications for 100 open positions for the new facility. ... Lantana Road will serve as the chain,s corporate headquarters and ...
(Date:8/20/2014)... 2014 Trovagene, Inc. (NASDAQ:   TROV), a ... from two clinical studies will be presented at the ... diagnostic test for the detection of high risk strains ... to take place in Seattle ... Additionally, a new U.S. patent was issued earlier this ...
(Date:8/20/2014)... Texas , Aug. 20, 2014  Quantum ... five diverse sets of patent families from Bayer Technology ... innovation driver for Bayer AG of Leverkusen, ... patents acquired provide broad intellectual property protection for ... economical high-volume quantum dot (QD) manufacturing. In addition, ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4
(Date:8/20/2014)... 20, 2014 According to a ... "Multiplexed Diagnostics Market (Technologies: Very High, High, Medium, ... Disease Diagnosis, Oncology, Autoimmune Diseases, Cardiac, Allergies and ... Trends and Forecast, 2013 - 2019", the global ... billion in 2012 and is expected to grow ...
(Date:8/20/2014)... A survey of U.S. veterans receiving mental health services ... also significant room for improvement among all areas studied. ... 2009, found that patients with a substance use disorder ... health services. Those with substance abuse problems also were ... to them or respected their decisions. , The findings, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 IQ Formulations ... was named to the Inc. 500 , distinguishing it ... United States. IQ Formulations not only made the list, but ... 5,486 percent over the past three years. It also ranked ... state of Florida and the second fastest growing company in ...
(Date:8/20/2014)... San Mateo, CA (PRWEB) August 20, 2014 ... their newest product—the Really Little Green Pouch —to ... easier to feed babies and toddlers homemade foods. ... says Little Green Pouch co-founder Maggie Crawford. She ... their kids, to limit exposure to things like pesticides ...
(Date:8/20/2014)... News) -- Taking the widely used antibiotic ... heart-related causes, a new study suggests. Because millions ... require urgent confirmation, said the Danish researchers behind the ... small and that guidelines for the use of the ... available. One heart expert wasn,t surprised by the ...
Breaking Medicine News(10 mins):Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Survey finds veterans generally satisfied with mental health care 2Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Antibiotic Might Raise Heart Risks for Some 2
... most populous city in Australia, with a population of over ... it is also the state capital of New South Wales. ... of the world in energy conservation, in the fight against ... to many areas for an hour. ,Lights were ...
... parties along with activists and film personalities have expressed ... and have vowed to fight it. ,Around ... malnutrition and half of them may die in the ... of Citizen Alliance, who are visiting the villages in ...
... Dana-Farber Cancer Institute have shown in a laboratory study ... counteracts// the damage caused by a form of muscular ... of Genes and Development, the researchers demonstrated that manipulating ... the muscles of mice with Duchenne muscular dystrophy, slowing ...
... at The University of Manchester have discovered that arthritis ... is processed in the //parts of the brain concerned ... Dr Bhavna Kulkarni has captured the first images of ... tomography (PET) scanners based at the Christie Hospital. ...
... till it is six months old could cut the ... ,The Human Immunodeficiency Virus (HIV) is a life-threatening ... to fail. ,Hoosen Coovadia and other researchers ... at the University of KwaZulu-Natal, South Africa, compared solely ...
... pharmaceutical giant, has agreed to stop selling Zelnorm, a ... chances of heart attack and stroke. , ,Officials of ... advised the firm to pull the drug out of the ... its patent application for a cancer drug by Indian authorities. ...
Cached Medicine News:Health News:MPs Vow to Fight Malnutrition in Madhya Pradesh 2Health News:Switching Genes to Overdrive Improves Muscular Dystrophy Symptoms in Mice 2Health News:Arthritis Pain Processed in Brain’s 'fear Zone,' First PET Scans Revea 2Health News:Breastfeeding Could Cut HIV Risk to Babies 2Health News:Constipation Drug Linked to Heart Attack Pulled Out 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: